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Parkinson’s disease (PD) is the second most common neurodegenerative disorder
next to Alzheimer’s disease. Most PD cases are considered to be sporadic and
despite considerable scientific effort, the underlying cause(s) still remain(s) enigmatic.
In particular, it is unknown to which extent epigenetic alterations contribute to the
pathophysiology of this devastating disorder. This is partly due to the fact that
appropriate PD models are not yet available. Moreover, epigenetic patterns and
mechanisms are species specific and murine systems reflect only a few of the
idiosyncrasies of human neurons. For several years now, patient-specific stem cell-
derived neural and non-neural cells have been employed to overcome this limitation
allowing the analysis and establishment of humanized disease models for PD. Thus,
several studies tried to dissect epigenetic alterations such as aberrant DNA methylation
or microRNA patterns using lund human mesencephalic cell lines or neurons derived
from (patient-specific) induced pluripotent stem cells. These studies demonstrate that
human neurons have the potential to be used as model systems for the study of
epigenetic modifications in PD such as characterizing epigenetic changes, correlating
epigenetic changes to gene expression alterations and hopefully using these insights for
the development of novel therapeutics. However, more research is required to define the
epigenetic (age-associated) landscape of human in vitro neurons and compare these to
native neurons before they can be established as suitable models for epigenetic studies
in PD. In this review, we summarize the knowledge about epigenetic studies performed
on human neuronal PD models, and we discuss advantages and current limitations of
these (stem cell-derived) neuronal models for the study of epigenetic alterations in PD.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting 1–2% of
the population aged>65 years (Tanner and Goldman, 1996). The vast majority (>90%) of PD cases
are non-familial and are considered to be sporadic (sPD) (Deng et al., 2018). Despite considerable
scientific effort in the last decades, the underlying cause for sPD still remains enigmatic. Not a
single cause, but rather several mechanisms appear to underlie the individual susceptibility of sPD
(Marras and Lang, 2013). Indeed, several cluster analysis of clinical features identified subtypes in
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PD pointing to different clinic phenotypes which may correspond
to different gene-environment interactions and individual
susceptibility (Erro et al., 2013).
Epigenetic alterations of genes could contribute to the
pathophysiology of this individual susceptibility (Landgrave-
Gomez et al., 2015). Epigenetic modifications comprise
DNA methylation, modification of histones, non-coding RNA
regulation, RNA editing and nucleosome remodeling/positioning
(Figure 1A) (Portela and Esteller, 2010; Wen et al., 2016; Qureshi
and Mehler, 2018). These epigenetic modifications regulate
gene expression without impact on the DNA sequence itself
(Portela and Esteller, 2010; Wen et al., 2016; Qureshi and Mehler,
2018). Epigenetic modifications regulate fundamental cellular
processes (e.g., gene transcription, X-chromosome inactivation)
and fill the gap between environmental and age-associated gene
expression (Wen et al., 2016; Qureshi and Mehler, 2018). They
are dynamic, cell specific, display interindividual variability and
can also occur in non-dividing cells such as neurons (Fraga
et al., 2005; Feng et al., 2007; Fraga and Esteller, 2007). DNA
methylation in particular modulates gene expression at promoter
or intragenic loci and importantly also via modification of
(regulatory), non-coding DNA-sequences (Wullner et al., 2016).
Epigenetic patterns change in cancer tissue (Figure 1B) and
upon aging (Figure 1B) in various organs and the analysis of
DNA methylation levels can provide an independent indicator
of aging (i.e., the “epigenetic clock”) (Horvath, 2013). Mutations
of epigenetic regulatory genes in neurological diseases include
DNA methyltransferases [DNMT1, hereditary sensory and
autonomic neuropathy type 1 (Klein et al., 2011)], histone
transferases [CREB binding protein, Rubinstein-Taybi syndrome
(Petrif et al., 1995)], or Methyl-CpG-binding proteins [MeCP2,
Rett syndrome (Amir et al., 1999)]. In addition, mutations
in genes can lead to secondary epigenetic modifications. For
example, CGG expansion mutations in the fragile X mental
retardation 1 (FMR1) gene result in hypermethylation of
the 5′ UTR of FMR1 in patients, leading to decreased FMR1
protein levels (Liu et al., 2018). Furthermore, different groups
of cortical genes undergo profound and characteristic age-
dependent DNA methylation alterations (Siegmund et al.,
2007). In general, aging is associated with a global decrease in
DNA methylation levels and aged monozygotic twins display
significant epigenetic differences, a process referred to as
epigenetic drift (Fraga et al., 2005; Teschendorff et al., 2013).
Profound cortical DNA methylation differences have been
reported in monozygotic twins discordant for Alzheimer’s
disease (Mastroeni et al., 2009).
Elevated expression of α-synuclein, an important key player
in PD, has been linked to the development of PD (Singleton
et al., 2003; Ibáñez et al., 2004). Thus, studies tried to identify
DNA methylation alterations of the α-synuclein gene (SNCA)
(Spillantini et al., 1997; Jowaed et al., 2010; Matsumoto et al.,
2010; de Boni et al., 2011). However, these findings remain
controversial as some studies identified DNA methylation
alterations of SNCA in post-mortem brain tissue from PD
patients (Jowaed et al., 2010; Matsumoto et al., 2010; Desplats
et al., 2011), whereas others could not replicate these findings
(de Boni et al., 2011; Guhathakurta et al., 2017).
The in-depth analysis of presumed epigenetic alterations in
sPD is hampered by the lack of appropriate sPD models. Several
phenomena have to be considered:
(I) Neurodegenerative diseases (NDDs) do not have any
equivalents in the animal kingdom and are specific to
humans except for some rare examples in aged dolphins
or baboons which are not dispensable for research
(Lowenstine et al., 2016; Gunn-Moore et al., 2018).
(II) Epigenetics both in terms of structure (DNA
methylation), histone code and functional interplay of the
various enzymes are species specific (Mendizabal et al.,
2014; Lowdon et al., 2016). Thus, murine (or other) model
systems are not representative for human conditions.
(III) NDD occur as non-familial diseases in the vast
majority of cases. A limited number of autosomal (and
recessive) mutations have been identified. Exploring these
inherited forms in transgenic cell culture and animal
models to transfer the results to the sporadic cases
has been the mainstream research strategy for the past
30 years. However, at least in PD, the discovery and
exploitation has not resulted in a decisive clue to the
etiology of the non-familial PD cases. Clinical trials of
compounds identified in several transgenic and toxin
models have failed (Olanow et al., 2008; Löhle and
Reichmann, 2010).
(IV) More appropriate disease models, i.e., living human
neurons have become available only recently.
CHALLENGES CHOOSING THE RIGHT
MODEL TO STUDY EPIGENETIC
ALTERATIONS IN sPD
To date, there is no decisive clue to the aetiology of sPD
and consequently no causal treatment. This lack of knowledge
represents a tremendous burden for the patients, their families
and caregivers. PD treatment relies on symptomatic therapies,
neither slowing nor halting the process of neurodegeneration.
Further, a biomarker identifying PD patients before the onset
of motor symptoms, i.e., before pronounced neurodegeneration,
is lacking. Thus, the development of novel therapeutics is
challenged and current clinical trials (e.g., Isradipine, phase III)
try to focus on early PD patients not requiring a symptomatic
therapy (Biglan et al., 2017). Moreover, current animal models
do not fully reflect the underlying pathology and hallmarks of
PD and despite huge efforts, could not elucidate the underlying
causal pathology towards sPD. The analyses of native brain tissue
is thus necessary, but limited to post-mortem tissue, which is not
suited for mechanistic studies. Studies on epigenetic alterations
using native bulk post-mortem brain tissue generated conflicting
results (Jowaed et al., 2010; de Boni et al., 2011).
Common cellular human models comprise the neuroblastoma
cell line SK-N-SH and its subclone SH-SY5Y. Indeed, these
cancer cells helped to identify important pathways and
mechanisms in PD, e.g., mitochondrial dysfunction or impaired
autophagy (Zeng et al., 2018). Upon treatment of SK-N-SH cells
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FIGURE 1 | Epigenetic modifications. (A) Schematic of epigenetic modifications comprising DNA methylation, histone modifications, and microRNA. RISC,
RNA-induced silencing complex. (B) Schematic of possible epigenetic modifications during aging and in cancer tissue. LINE, long interspersed nuclear element;
MIR, microRNA.
with the DNMT inhibitor 5-Azacytidine, DNA demethylation
of the SNCA intron 1 was associated with an increase in
SNCA mRNA and α-synuclein protein expression (Jowaed et al.,
2010). To date, these findings could not be replicated in
human neurons due to the inaccessibility of living disease-
affected cells. It remains to be determined whether alteration in
cis or yet undetermined exogenous factors underly epigenetic
modifications of the SNCA gene.
Epigenetic variation plays an important role in evolution
(Richards, 2008; Mendizabal et al., 2014). Many animal genomes
(mostly vertebrates) are depleted of CpG dinucleotides and
genes associated with neurological functions exhibit human-
specific patterns of DNA methylation (Mendizabal et al., 2014).
Whole-genome DNA methylation analysis of prefrontal cortical
tissue of humans and chimpanzees revealed extensive species-
specific variation associated with strong gene expression changes
(Zeng et al., 2012). Moreover, it has already been demonstrated
on a single-cell level that mouse and human embryos are
characterized by distinct differences in DNA methylation and
histone modification patterns (Chavez et al., 2014).
To date, there is no decisive clue to the etiology of sPD
and consequently no causal treatment. This lack of knowledge
represents a tremendous burden for the patients, their families
and caregivers. PD treatment relies on symptomatic therapies,
neither slowing nor halting the process of neurodegeneration.
Further, the lack of a biomarker which would identify PD
patients before the onset of motor symptoms, i.e., before
pronounced neurodegeneration has occurred. Current clinical
trials (e.g., Isradipine, phase III) try to focus on early PD
patients not requiring a symptomatic therapy (Biglan et al.,
2017). Isradipine was identified in epidemiological studies and
has shown “rejuvenating” effects in vitro and in vivo models. It is
supposed that Isradipine blocks L-type Ca(v)1.3 Ca2+ channels
maintaining their rhythmic pacemaking which in turn results in
decreased vulnerability of the neuron to cell stressors (Chan et al.,
2007). It remains to be determined whether the current clinical
trial, in contrast to the previous trials of compounds identified
in transgenic and toxin models will be successful (Olanow et al.,
2008; Löhle and Reichmann, 2010).
More appropriate disease models, i.e., living human neurons
have become available only recently and could be used
to study epigenetic modifications in PD. Two immortalized
human male fetal neural precursor lines were developed from
cortex (CX) and the ventral mesencephalon (VM) carrying
the c-myc or v-myc oncogene, respectively. These so-called
ReNcell CX and VM express typical markers for neural
precursor cells and upon differentiation, ReNcell VM showed
positive staining for tyrosine hydroxylase (Donato et al., 2007).
Another mesencephalic human cell line was derived from 8-
week-old female human ventral mesencephalic tissue and a
subclone, the lund human mesencephalic (LUHMES) cell line,
can be differentiated into morphologically and biochemically
mature dopamine-like neurons (Lotharius et al., 2005). The
advantage of these cell lines is that they consist of a quite
homogenous population, have the ability to be cultured and
expanded long-term, have the capacity to be differentiated
into more mature post-mitotic dopaminergic phenotypes and
are suitable for to novel genetic editing tools such as the
Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR)/Cas system.
Human stem cell-derived neurons can be generated from
embryonic stem cells (ESC), induced pluripotent stem cells
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(iPSCs) or tissue-specific (stem) cells. ESC are obtained from the
inner cell mass of the blastocyst and are pluripotent (Thomson
et al., 1998; Dhara and Stice, 2008). Diverse protocols were
utilized to directly differentiate ESC into neural (and glial)
cells under defined culture conditions using different factors,
signaling molecules, supplements, and additives (Dhara and
Stice, 2008). Differentiated cells such as fibroblasts can be
reprogrammed by defined factors to iPSC resetting an embryonic
state (Nakagawa et al., 2008; Eguchi and Kuboki, 2016). IPSC
can be derived from patients and controls allowing the study
of disease- and non-affected defined neuronal populations and
other cellular subtypes. Tissue specific cells such as dermal
(Joannides et al., 2004) or mesenchymal stem cells (Singh
et al., 2017) can also be differentiated into neural cells. Direct
conversion – omitting a pluripotent intermediate state – of
somatic cells into so-called induced neurons (iN) exhibiting
typical neuronal and differentiation properties is achieved by
defined transcription factors (Ladewig et al., 2012; Prasad
et al., 2016; Xu et al., 2017). Regarding PD, most attempts
have focused on generating in vitro DAn to study disease-
related mechanisms as cardinal motor manifestations of PD
refer to the progressive loss of DAn. Stem cell-derived DAn
were generated by many research groups using quite different
approaches and culture conditions. Most protocols are based
on activation of the important Sonic Hedgehog and WNT
signaling pathway in combination with floor plate based and
feeder cell protocols or other small molecules and together
with transcription factors required for proper DAn specification
such as FOXA2, LMX1A, or Oct4 (Chen et al., 2009; Cooper
et al., 2010; Deleidi et al., 2011; Kriks et al., 2011; Kirkeby
et al., 2012; Arenas et al., 2015; Fernandez-Santiago et al.,
2015; Fedele et al., 2017; Qiu et al., 2017). Other protocols
used retinoic acid (Tsai et al., 2015), Vitamin C (Wulansari
et al., 2017), supplementation with steroids (Agbay et al.,
2018), FGF20 (Correia et al., 2007), or plating in Lam-111
(Kirkeby et al., 2017) to increase the yield of DAn. Indeed, the
attempt to study a defined and especially vulnerable neuronal
population is imperative. However, it should be noted that
the marker expression and efficiency generating DAn vary
highly depending on the applied protocol (Xu et al., 2017).
Thus, observed PD related phenotypes (i.e., mitochondrial
dysfunction, α-synuclein accumulation, synaptic dysfunction)
might not be solely linked to DAn. PD related phenotypes
have nevertheless been detected in iPSC-derived DAn and
neurons from PARK2/Parkin (Imaizumi et al., 2012; Ren et al.,
2015; Chung et al., 2016), PINK1 patients (Chung et al.,
2016), PD patients carrying glucocerebrosidase (GBA) mutations
(Schondorf et al., 2014; Woodard et al., 2014; Aflaki et al., 2016;
Fernandes et al., 2016; Yang et al., 2017), patients harboring the
SNCA triplication mutation (Byers et al., 2011; Flierl et al., 2014;
Oliveira et al., 2015), and in iPSC-derived DAn and sensory
neurons from patients carrying leucine-rich repeat kinase 2
(LRRK2) mutations (Nguyen et al., 2011; Bahnassawy et al., 2013;
Schwab and Ebert, 2015; Hsieh et al., 2016; Lopez de Maturana
et al., 2016; Sandor et al., 2017; Schwab et al., 2017). Several
studies have already tried to decipher mechanistic processes
and tested drugs using iPSC-derived DAn: DAn from SNCA
triplication carriers secreted high levels of α-synuclein which
was taken up by neighboring neurons (Reyes et al., 2015).
FACS-sorted post-mortem DAn from LRRK2-G2019S carriers
displayed a distinct transcriptome compared to post-mortem
DAn from non-affected individuals and these DAn also expressed
a distinct set of genes compared to control DAn (Sandor et al.,
2017). Clioquinol, a compound known to alleviate dopamine
neuron loss, rescued these pathogenic expression changes
(Sandor et al., 2017). The macrolide compound rapamycine and
the PGC1α-transcription factor inducing disaccharide trehalose
protected against mitochondrial neurotoxicity in iPSC-derived
DAn exhibiting the Parkin Q311X mutation (Siddiqui et al.,
2015). High-throughput screening identified the compounds
NCGC607 and NCGC00188758 and the chaperone ambroxol,
which restore glucocerebrosidase activity and rescue PD-
related phenotypes in DAn from GBA carriers (Aflaki et al.,
2016; Mazzulli et al., 2016; Yang et al., 2017). The effect of
NCGC00188758 was confirmed in iPSC-derived DAn of SNCA
triplication, SNCA A53T, sPD and PARK9 patients (Mazzulli
et al., 2016). These aforementioned studies however bear only
little impact regarding the pathophysiological processes of sPD.
It remains to be determined whether human (patient-specific)
neurons might also be used to generate useful models to
identify novel pathophysiological processes to such as epigenetic
modifications in PD.
EPIGENETIC STUDIES IN HUMAN
NEURONS
Epigenetic Studies Using Immortalized
Human Fetal-Derived Neurons
HDACi Rescue WT α-Synuclein-Induced DNA
Damage in LUHMES Cells
Paiva et al. (2017) demonstrated transcriptional deregulation
(e.g., downregulation of the dopamine receptor; DAT) in
α-synuclein wild type (WT) and A30P lentiviral transfected
LUHMES cells differentiated for 8 days (Table 1). RNAseq
demonstrated a downregulation of DNA repair genes
due to the overexpression of WT and A30P α-synuclein.
The expression of WT α-synuclein was associated with a
significant reduction in the levels of acetylated Histone
3 and treatment of cells using the HDACi sodium
butyrate could ameliorate the observed phenotype. These
results were confirmed in LUHMES cells treated with
1-methyl-4-phenylpyridinium (MPP+).
PD-Risk SNPs Are Enriched in Enhancers in DAn
From LUHMES Cells
Pierce et al. (2018) evaluated genome-wide histone H3K27
acetylation, CCCTC-binding factor (CTCF) occupancy, and RNA
expression in differentiated (6–7 days old) and undifferentiated
LUHMES cells (Table 1). The differentiation into DAn was
accompanied by distinct changes in gene expression. 57,905
genes were mapped in total and 6,147 genes were significantly
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VM, ventral mesencephalon; DAn, dopaminergic neurons; MIR, micro RNA; siRNA, small interfering RNA; shRNA, short hairpin RNA; qRT-PCR, quantitative
reverse transcription-polymerase chain reaction; WB, western blot; Seq, sequencing; HDACi, histone deacetylase inhibitors; WT, wild type; KO, knock out; α-Syn,
α-synuclein; IRES, internal ribosome entry site; GFP, green fluorescent protein; ROS, reactive oxygen species; (s)PD, (sporadic) Parkinson’s disease; SNP, single
nucleotide polymorphism.
downregulated whereas 7,621 genes were significantly up-
regulated. Chip-Seq revealed 25,000 active enhancers, 12,000
active promoters, and 40,000 occupied CTCF sites between
differentiated and undifferentiated LUHMES cells. PD-risk SNPs
were enriched in enhancers for synapse and vesicle trafficking
categories in DAn from LUHMES. However, the fold-change to
enhancer location explained only 10% of variability in their data
set. The authors suggested that enhancers do not only control
the expression of single genes, but many genes are affected by
particular loci.
MIR-7 Is Cytoprotective and Exhibits Anti-Neurotoxic
Effects in ReNcells
MIR are small, highly conserved, sequence-specific non-coding
RNA molecules regulating post-transcriptional gene expression
(Sato et al., 2011) (Table 1). Concerning MIR alterations,
the group of E. Junn showed that lentiviral overexpressed
MIR-7 promoted glycolysis via downregulation of RelA in
2 weeks old ReNcell (human ventral mesencephalic neural
progenitor)-derived DAn (Chaudhuri et al., 2015). MIR-7
is highly expressed in the brain, including DAn from the
Substantia nigra. In their cell model, MIR-7 also increased
the expression of the Glucose Transporter Glut3 and finally
resulted in cytoprotection and exhibition of anti-neurotoxic
effect after treatment with MPP+. The authors pointed out
that an intact glycolytic pathway is necessary for neuronal
survival and promoting effects of MIR-7 could be beneficial in
PD. In a subsequent study, Choi et al. (2018) demonstrated
that overexpression of MIR-7 in ReNcells resulted in a
decrease of monomeric and high molecular weight forms
of α-synuclein (Table 1). Interestingly, α-synuclein aggregates
due to transfection of preformed α-synuclein fibrils were also
diminished. The authors could show that an increased autophagic
reflux promoting α-synuclein clearance was responsible for the
observed effects.
MIR-221 Expression Is Modulated by WT DJ1 to
Execute Cytoprotective Effects
DJ1 (PARK7) mutations lead to fPD (Bonifati et al., 2003).
Thus, Oh et al. (2018) used an array-based screen to identify
RNA transcripts regulated by DJ1 (Table 1). Using SH-SY5Y
cells, they demonstrated that MIR-221 exhibited a 55% reduction
of expression in DJ1 knock out (KO) cells and confirmed
these findings via qRT-PCR as well as using a DJ1 KO mouse
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model. Solely the WT DJ1 protein seems to influence MIR-
221 expression levels through the MAPK/ERK pathway. They
further consolidated these findings in ReNcell VM showing
that lentiviral transfection of MIR-221 was cytoprotective
in DJ1 KO cells.
Overall, these studies demonstrated various epigenetic PD-
associated changes in fetal human neurons. Their impact on PD
pathogenesis requires further studies, especially using patient-
specific neurons derived from aged individuals.
Epigenetic Studies in iPSC-Derived
Neurons From PD Patients
Aberrant DNA Methylation Profiles in iPSC-Derived
DAn From PD Patients
Fernandez-Santiago et al. (2015) demonstrated that iPSC-derived
DAn from PD patients exhibit an aberrant DNA methylation
pattern compared to controls (Table 2). They differentiated
fibroblast-derived iPSC into 30 days old dopaminergic neurons
TABLE 2 | Epigenetic studies in human iPSC-derived neurons.
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DAn, dopaminergic neurons; n.a., not applicable; MIR, micro RNA; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; WB, western blot; Seq,
sequencing; HDAC, histone deacetylases; (s)PD, (sporadic) Parkinson’s disease; iPSC, induced pluripotent stem cells; LRRK2, leucine-rich repeat kinase; UTR,
untranslated region; IP, immunoprecipitation; TRIM23, tripartite motif containing 23; GBA, glucosylceramidase beta; gRNA-dCAS9-DNMT3A, guide RNA-deactivated
Cas9-DNA methyltransferase 3A.
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of the A9 subtype. In total, they generated DAn from four PD
patients carrying LRRK2 mutations (G2019S, L2PD), six sPD
patients and four controls. The expression of DAn markers
ranged from 44 to 67%. Applying array-based analysis for DNA
methylation (450K, Illumina) and gene expression (Genechip
Human Exon 1.0 ST, Affymetrix) this study demonstrated
that L2PD and sPD exhibit similar DNA methylation and
gene expression profiles. DAn from L2PD and sPD patients
showed an aberrant DNA methylation and gene expression
profile compared to fibroblasts, iPSC and non-dopaminergic
neurons from PD patients and controls. DNA methylation
alterations in DAn were enriched in enhancer elements,
transcription factor (TF) binding sites and were partially
correlated with gene expression alterations validated via qRT-
PCR. Upregulated TFs and proteins included e.g., OTX2/PAX6
or SNCA/DCC. The authors noted that DAn from PD patients
might have undergone incomplete epigenomic remodeling
compared to controls. The study showed an aberrant DNA
methylation profile in DAn only – not other non-dopaminergic
phenotypes - and very similar DNA methylations differences
in DAn derived from the fPD and sPD cases. It is quite
remarkable that familial and idiopathic PD cases show common
epigenetic modifications in the most vulnerable neuronal
subtype affected in PD.
Altered MIR Profiles in iPSC-Derived DAn From PD
Patients
Tolosa et al. identified MIR alterations in DAn from sPD
and L2PD patients compared to controls (Tolosa et al.,
2018) (Table 2). They used the very same samples as in
the study of Fernandez Santiago et al. (Fernandez-Santiago
et al., 2015). They first performed array-based and qPCR
analyses to identify differentially expressed MIR. Different
computational approaches were then applied to perform
enrichment analysis and to compare the results with global
gene expression data from the previous study. The functional
analysis revealed two main clusters associated with proper
neuronal (cluster 1) and diverse homeostatic (cluster 2)
functions. Interestingly, the alterations were again identified in
DAn from sPD and L2PD patients to a very similar extent.
MIR alterations involved up- and downregulated MIR. These
expression differences seem to display early molecular changes
preceeding neuropathological cellular PD phenotypes such as
inclusion formation.
TRIM23 Reverses Impaired LRRK2-Mediated MIR
Let-7a Activity in Neuronal Epithelial Cells
Tripartite Motif Containing 23 (TRIM23) has been described
as an activator of MIR-associated proteins and is supposed
to regulate SNCA (Schwamborn et al., 2009; Pavlou et al.,
2017). Gonzalez-Cano et al. (2018) showed that LRRK2,
TRIM23, argonaute protein 2 and the MIR Let-7a interact
in vitro and in vivo (Table 2). Vector-mediated expression
of GFP-tagged TRIM23 and/or fly-tagged LRRK2-RR141H in
neuronal epithelial cells (differentiated for 48 h) suggested that
LRRK2 inhibits MIR Let-7a resulting in impaired neuronal
differentiation. These effects could be antagonized by TRIM23
expression to some extent.
The SNCA 3′ UTR Contains Conserved MIR Binding
Sites in iPSC-Derived Cholinergic Neurons
Tagliafierro et al. (2018) tried to identify conserved MIR
binding sites at the 3′ UTR of SNCA (Table 2). They
carried out a computational approach and further validated
the MIR expression in iPSC-derived forebrain cholinergic
neurons (45–50 days old) from a SNCA triplication patient
and 1 control cell line. The SNCA 3′ UTR exhibited four
conserved binding sites for MIR-7-5p, MIR-140-3p, MIR-
153-3p, and MIR-223-3p. It has been previously shown
that MIR-7 and MIR-153 regulate SNCA mRNA expression
levels (Junn et al., 2009; Doxakis, 2010) and MIR-223 is
involved in the differentiation of mature neurons (Harraz
et al., 2014). However, the expression levels of all 4 MIR
varied between iPSC, neural precursor cells and iPSC-derived
neurons. Moreover, an association between genetic variants
of the 3′ UTR and the conserved MIR binding sites could
not be established.
MIR-22-3p Is Downregulated in iPSC-Derived DAn
From PD Patients Carrying GBA Mutations
Straniero et al. (2017) focused on GBA expression regulation
evaluating the effect of the MIR-22-3p and MIR-132 (Table 2).
Preliminary analysis in HEK293 and HeLa cells demonstrated,
that MIR-22-3p targets GBA and the GBA pseudogene
GBAP1. These findings were validated in 35 days old
iPSC-derived DAn from six controls and four PD patients
carrying GBA mutations according to the differentiation
protocol of Kriks et al. (2011). Upon neuronal differentiation,
GBA and GBAP1 were up-regulated and MIR-22-3p was
downregulated in control DAn compared to the neuronal
precursors. GBA transcripts were downregulated in iPSC-
derived DAn from PD patients accompanied by a slight
up-regulation of MIR-22-3p. Though a connection between
the RNA-based network and PD pathology has not been firmly
established, the results point toward a possible link between
GBA/GBAP1and MIR-22-3p.
HDAC4 Mislocalization Leads to Protein
Dyshomeostasis in iPSC-Derived DAn From
GBA-N370S Patients
Another link between GBA mutations and epigenetic alterations
was proposed by Lang et al. (2018) (Table 2). They observed
an increase in nuclear localization of HDAC4 in iPSC-
derived DAn from PD GBA-N370S patients compared to
controls. Non-dopaminergic neurons did not exhibit this
phenotype. The mislocalization of HDAC4 was associated
with a downregulation of HDAC4-controlled genes. It is
exciting that four compounds – used in other diseases
such as prostate cancer – targeted HDAC4 activity, reversed
the impaired expression of the HDAC4-controlled genes
and subsequently ameliorated pertubations in autophagy and
lysosomal pathways. Furthermore, these findings were also
confirmed in four sPD cases.
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DNA Methylation Editing of the SNCA Intron 1
Results in Gene Downregulation and Improvement of
PD Phenotypes in iPSC-Derived Neuronal DA
Progenitor Cell Lines
As already mentioned, the SNCA intron 1 might be a putative
promoter region regulating SNCA expression (Jowaed et al.,
2010). Thus, Kantor et al. (2018) generated guide RNA
(gRNA)-deactivated Cas9 (dCas9)-DNMT3A lentiviral vectors
and increased the DNA methylation levels at the SNCA
intron 1 in neuronal DA progenitors from a patient with
a SNCA triplication mutation (Table 2). The targeted DNA
methylation editing resulted in decreased SNCA expression,
reduced mRNA/protein levels and improved pathological
phenotypes (superoxide production, cell viability) in the iPSC-
derived neuronal DA progenitors. The transgenes increased
the methylation levels across several CpGs of the SNCA
intron 1 with minimal effects on global DNA methylation
levels or expression of certain selected genes. CpG 6 and 7
of the SNCA intron 1 seemed to be major target sites. To
the best of our knowledge, this is the first study showing
mechanistic epigenetic analysis and their direct impact on
gene expression being not only relevant for fPD but also
sPD. We would like to point out that such studies indeed
require human neurons and cannot be performed using post-
mortem brain tissue.
PERSPECTIVES
Human neuronal cells bear promising potential to study
epigenetic alterations. Several studies already identified
characteristic features with regard to DNA methylation,
MIR and histone modifications in human neuronal in vitro PD
models. These findings are quite encouraging and point toward
possible epigenetic pathophysiological processes in PD. This will
hopefully lead to the development of novel therapeutic strategies
– however a definite confirmation of such findings in vivo and of
re-juvenation awaits clarification.
Human iPSC-derived neurons offer several advantages over
other cellular and in vivo models. They
• are patient-derived
• can be obtained in an unlimited amount
• offer the possibility to generate highly pure neuronal
populations
• are available for co-culture studies or generating 3D brain
(cerebral organoids) better recapitulating the native cerebral
environment, as astrocytes and microglia are considered to
be implicated in the pathogenesis of PD (Fellner et al., 2011;
Booth et al., 2017; Subramaniam and Federoff, 2017)
• allow the direct investigation of the presumed effects of
epigenetic alterations on gene expression
• allow high-throughput screening
• are accessible for gene editing
However, it is under intense scrutiny whether human
neuronal cellular models are appropriate to study epigenetic
modifications. Particularly, fetal neurons might not be suitable
to study age-associated epigenetic patterns related to NDD.
Concerning iPSC-derived neurons, three major caveats have to
be addressed:
(1) The process of directed reprogramming itself is based on
epigenetic modifications (Rando and Chang, 2012).
(2) Reprogramming resets the epigenetic pattern almost
to zero (“epigenetic rejuvenation”), impairing studies of age-
associated alterations (Rando and Chang, 2012).
(3) The epigenome of iPSC-derived neurons might differ
substantially from native neurons.
These three issues have yet to be resolved. It has already
been demonstrated, using isogenic human neural stem cell
systems, that the reprogramming process itself does not lead
to an aberrant DNA methylation or gene expression pattern
(Choi et al., 2015; de Boni et al., 2018). To overcome the
limitation of epigenetic rejuvenation, fibroblast-derived neurons
were generated via direct conversion omitting a pluripotent
state (Mertens et al., 2015). However, preservation of age-
associated signatures was not replicated in a current study
generating directly converted neurons without the use of
Oct4 (Sheng et al., 2018). Another approach was proposed
by introducing progerin, a truncated version of lamin A
protein involved in Hutchinson–Gilford progeria syndrome
(Miller et al., 2013). The authors suggested that the lack of
a distinct neurodegenerative phenotype, especially neuronal
protein inclusions, could be due to the age-reset during
reprogramming (Miller et al., 2013). Indeed, the analysis of DAn
grafts exhibiting progerin overexpression in mice demonstrated
large multilamellar inclusions which are considered to be
precursors of Lewy bodies (Miller et al., 2013).
However, a dysregulation of progerin expression has not been
observed in PD. Moreover, it has been shown that the genetic
background and differentiation protocols have a high impact
on the epigenetic landscape in iPSC-derived neurons (de Boni
et al., 2018). Comparing iPSC-derived forebrain neurons to
native, post-mortem temporal lobe bulk brain tissue, it has been
shown that upon neuronal differentiation, differences in actively
transcribed genes, long intergenic non-coding RNAs (lincRNA),
and DNA methylation patterns were diminished (Hjelm et al.,
2013). IPSC-derived neurons differentiated for 140 days exhibited
<25% gene expression, <16% lincRNA, and <30% DNA
methylation differences compared to native brain tissue (Hjelm
et al., 2013). Single gene analysis demonstrated variable gene
expression patterns for neuronal, astrocytic, or oligodendroglial
markers: some markers are remarkably similar to native brain
tissue [e.g., microtubule-associated protein 2 (MAP2) or the
serine/threonine protein kinase 6 (PAK6)], some increased [e.g.,
Tubulin Beta 3 Class III (TUBB3) or neurotrophic growth
factor (NGF)], whereas astrocytic and oligodendroglial markers
remained downregulated [e.g., oligodendrocyte transcription
factor 2 (Olig2) or glial fibrillary acidic protein (GFAP)], possibly
due to the optimization of in vitro cell culture conditions for
neuronal differentiation (Hjelm et al., 2013). Moreover, iPSC-
derived DAn exhibited substantially different gene expression
patterns and an incorrect anterior–posterior axis patterning
compared to native midbrain bulk tissue (Xia et al., 2016).
Genes associated with immature DAn were highly expressed
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in iPSC-derived DAn (Xia et al., 2016). In this context, a
comparison of iPSC-derived neurons to, e.g., FACS-sorted native
neurons is required. Using native laser-capture microdissected or
FACS-sorted neuronal populations (e.g., DAn and glutamatergic
neurons), recent studies have begun to demonstrate profound
epigenetic and transcriptomic differences between iPSC-
derived neurons and native neurons (Montaño et al., 2013;
Kozlenkov et al., 2014, 2015; Dong et al., 2018). However,
the precise epigenetic and transcriptomic landscape of
native neurons has yet to be determined and compared to
iPSC-derived neurons.
CONCLUSION
Human in vitro (patient-specific) neurons bear the potential
to generate useful tools to study epigenetic modifications
in PD. However, major efforts are still required to define
the epigenetic landscape of these neurons compared to
native neurons and determine age-associated epigenetic
patterns. First of all, native (single cell) epigenomic genome-
wide analyses, from, e.g., FACS-sorted brain tissue, have
to be performed to define the variation of the normal
epigenetic landscape of different neuronal and glial populations.
Including cells from aged individuals, such analyses could
be used to create a reference epigenome for further
epigenetic evaluations using human (patient-specific) in vitro
neurons. The epigenetic comparison of native and in vitro
human neurons could then help to improve current
differentiation protocols and might reveal whether observed
epigenetic changes in vitro indeed correspond to a PD or
other phenotypes.
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